First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

NCT06070740 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Neuroendocrine Carcinoma

Interventions

DRUG: Durvalumab and Chemotherapy(oxaliplatin and capecitabine)

Sponsor

Peking Union Medical College Hospital